Research Progress of Mavacamten in Hypertrophic Cardiomyopathy
NIU Dongdong
WANG Zhiping
Abstract：This article reviews the research progress of Mavacamten in hypertrophic cardiomyopathy (HCM). HCM is a hereditary cardiovascular disease. Mavacamten is a selective inhibitor of myosin ATPase, the first targeted drug at the molecular level for myocardial hypertrophy. This drug has successfully passed phase III trials, representing a major advancement in the treatment of HCM and opening new perspectives for the development of new drugs targeting the molecular substrate of hypertrophic cardiomyopathy.
Keywords：hypertrophic cardiomyopathyMavacamtenmyocardial actinreviews
Publication Date：2025-09-10
Online Publishing Date：2025-09-18(First online date of this platform, not the publication date of the document)
Pages：3( 2637-2639 )